Updated: Oct 19
Medically reviewed by ChinaCureLink Team
Table of Content
Why This Case Matters
This case follows Mrs. Fang (alias), a 70-year-old patient whose lymphoma relapsed repeatedly despite chemotherapy, a failed CAR-T attempt elsewhere, and a long list of complicating health issues — and who ultimately achieved complete remission through CAR-T cell therapy at a hospital in China specializing in hematology, even after her care team estimated her odds of success at under 10%. For international patients facing a similarly complex or high-risk lymphoma case — particularly those who've been told they're not eligible for CAR-T elsewhere — ChinaCureLink can help evaluate options and coordinate access to the kind of specialized, high-acuity care Mrs. Fang received.
Key Takeaways |
|
Patient Background
Mrs. Fang was first diagnosed with gastric MALT lymphoma in 2021, and treatment aimed at the underlying H. pylori infection brought temporary improvement. In January 2024, a PET-CT scan revealed widespread lymph node enlargement, and pathology confirmed the disease had transformed into an aggressive, activated B-cell subtype of diffuse large B-cell lymphoma.
She was treated at an outside hospital with six cycles of Pola-R-CHP followed by two cycles of R-GemOx chemoimmunotherapy, achieving complete remission on PET-CT — though treatment was complicated by recurrent atrial fibrillation. The remission didn't last: just three months later, in December 2024, her right leg began to swell, and a PET-CT scan revealed multiple new masses throughout her abdomen and pelvis. Treatment with a bispecific antibody therapy triggered a serious cytokine release syndrome reaction and a urinary tract infection, without controlling the tumor's growth.
The Care Team and Approach
By February 2025, Mrs. Fang began radiotherapy for the affected pelvic region and was admitted to a top hematology hospital in China in a severely debilitated state — her right thigh significantly swollen, unable to walk, and in considerable pain. Radiotherapy and supportive medication improved the leg swelling, but her disease progressed elsewhere: rising lactate dehydrogenase levels, growing lymph nodes, and worsening cardiac function. Repeat imaging showed extensive, high-burden disease throughout her body.
Given her age, her history of atrial fibrillation, and the real risk that aggressive treatment could trigger heart failure or dangerous complications, her care team faced a genuinely difficult calculation — but without active treatment, her prognosis was terminal. After extensive discussion with her family, Dr. Zhao Lei (pseudonym) and the care team decided to proceed with CAR-T therapy. Her T-cells were collected and a commercial CAR-T product prepared, while she began reduced-dose bridging chemotherapy to help control her disease in the meantime.
The bridging phase demanded close, round-the-clock monitoring. Her lymph nodes began shrinking within days, but she developed atrial fibrillation during activity, successfully managed with medication, followed by a more serious cardiac episode days later that required urgent cardiology involvement and was resolved by early afternoon. While waiting to return to the facility that had originally collected her cells for the actual infusion, she developed fungal pneumonia, a cytomegalovirus infection, and a bacterial infection, alongside intermittent atrial fibrillation. That facility determined she no longer met the criteria for re-infusion, and her lymphoma relapsed further during the delay, leaving her severely weakened.
Facing few remaining options, Mrs. Fang returned to the hospital specializing in hematology and CAR-T cell therapy. Her care team was direct about the risks: proceeding with CAR-T could worsen her active infections and trigger severe complications, including cytokine release syndrome, neurological toxicity, bleeding, and cardiac events — with an estimated success rate under 10% given her condition. Her family chose to proceed. Pretreatment began on March 21, and she received her CAR-T infusion on March 25.
Treatment Timeline/ Process
Before CAR-T
2021: Diagnosed with gastric MALT lymphoma; anti-H. pylori treatment brought temporary improvement
January 2024: PET-CT revealed widespread lymphadenopathy; pathology confirmed transformation to diffuse large B-cell lymphoma
Treated with Pola-R-CHP and R-GemOx chemoimmunotherapy at an outside hospital, achieving complete remission complicated by recurrent atrial fibrillation
December 2024: Relapsed with right leg swelling; PET-CT revealed multiple new abdominal and pelvic masses
Treated with a bispecific antibody therapy; developed serious CRS and a urinary tract infection, without controlling tumor growth
Bridging and Assessment
February 2025: Began radiotherapy; admitted severely debilitated, unable to walk
Leg swelling improved with radiotherapy, but disease progressed elsewhere, with rising LDH and growing lymph nodes
T-cells collected and commercial CAR-T product prepared; began reduced-dose bridging chemotherapy
Successfully managed two atrial fibrillation episodes during bridging while lymph nodes continued shrinking
Developed fungal pneumonia, CMV infection, and bacterial infection while awaiting infusion elsewhere; deemed ineligible for re-infusion at that facility as her lymphoma relapsed further
CAR-T Treatment and Recovery
Returned to the hospital and proceeded with CAR-T after family discussion of the risks
March 21: Began pretreatment
March 25: Received CAR-T infusion
Day 9: Developed a fever attributed to a CRS reaction, resolved with treatment
Day 10: CAR-T cell expansion testing showed strong proliferation
Following weeks: Lymph nodes continued to shrink and LDH gradually normalized
Day 28 (April 22): PET-CT confirmed complete remission
Outcome
Twenty-eight days after her CAR-T infusion, PET-CT imaging confirmed Mrs. Fang had achieved complete remission — a result that far exceeded the under-10% odds her care team had estimated going into treatment, given her age, cardiac history, and the multiple infections she was fighting at the time. She and her family received the news with tears of joy after a battle that spanned more than three years and multiple near-misses.
How ChinaCureLink Can Help International Patients to Access This Treatment
Mrs. Fang's case shows what's possible even in the most complex, high-risk presentations — multiple relapses, significant comorbidities, and a prior CAR-T attempt called off elsewhere. For international patients facing a similarly difficult lymphoma case, particularly those who've been told they're not eligible for CAR-T treatment at another hospital, ChinaCureLink helps evaluate options and coordinates access to hospitals experienced in managing this level of complexity, from case review through treatment and long-term follow-up.
Get a Second Opinion Before Fly to China
For suitable cases, ChinaCureLink can then coordinate an online consultation with the specialist to discuss the technical treatment details directly. The purpose is to help the patient understand which treatment option and which specialist center may be most appropriate before making an international treatment decision.
What Patients Say About ChinaCureLink & Medebound HEALTH
China CureLink operates under Medebound HEALTH — an internationally recognized healthcare navigation company incorporated in New York, with operations across North America and Asia-Pacific.
Rated 4.6 ⭐⭐⭐⭐⭐ at Trustpilot
Medebound HEALTH's online testimonials. Learn More
★★★★☆ Sarah Zhang · Canada· Jul 2024 · Verified “The interpreter during the video call was fantastic — super professional and answered all our questions clearly and quickly. The professor was also very patient and gave us detailed and honest guidance on our treatment options.” |
★★★★★ Andrew Goh · Singapore · Aug 2024 · Verified “My first contact with Medebound was over a year ago. Jason has always been responsive, even when I wasn't ready to proceed. When I finally did, the consultation was seamlessly arranged and the specialist was outstanding.” |
★★★★★ Daniel Wong · Singapore · Aug 2024 · Verified “I have dry eye and nothing seemed to be working, even with different medications. I heard about a medication from the U.S. that’s supposed to be really effective, but I didn’t want to try it without talking to a doctor first. MEDEBOUND connected me with a top ophthalmologist in the U.S. and it was so reassuring to get their expert advice.” |
★★★★☆ Pongsakorn · Thailand · Feb 2025 · Verified “Kiki at Medebound is amazing — so professional and helpful! They got my video consultation with an MD Anderson expert set up super fast, within just 5 working days. I am so grateful for their support.” |
Frequently Asked Questions
What if I've already been told I'm not eligible for CAR-T therapy at another hospital?
Eligibility criteria can vary significantly between hospitals and depend on a patient's current condition at the time of assessment. ChinaCureLink can help arrange a fresh case review with a hospital experienced in managing complex, high-risk CAR-T cases.
Can elderly patients or those with heart conditions safely receive CAR-T therapy?
It depends on the individual case. Patients with cardiac history or other comorbidities require closer monitoring and a carefully managed bridging period, but as this case shows, age and heart conditions alone don't automatically rule out CAR-T therapy. A specialist evaluation is needed to assess individual risk.
How can international patients access CAR-T therapy for relapsed lymphoma in China?
Access typically starts with a case review, where medical records, pathology, and treatment history are submitted for evaluation. ChinaCureLink coordinates this process and helps match patients with hospitals experienced in complex or previously unsuccessful CAR-T cases.
About ChinaCureLink
ChinaCureLink helps patients across the world access the best cancer treatment at China's top hospitals, without the delays, language barriers, and administrative confusion that typically come with seeking care abroad.
We connect patients directly with China's top cancer hospitals, ensuring that from the first case submission through to treatment and follow-up, every step is guided, translated, and coordinated by a team experienced in cross-border patient care.
ChinaCureLink is proudly affiliated with Medebound HEALTH — founded by US physicians, with over 10 years of experience and more than 3,000 patients served worldwide, Medebound HEALTH is recognized by Forbes and it is one of the most trusted patient cross-border concierge service company across North America and the Asia Pacific.
Disclaimer
This article is for informational purposes only and is not medical or financial advice. Treatment eligibility, protocols, and costs vary by individual case — confirm specifics with a coordinator and treating physician before making any decisions.
